AIM ImmunoTech Inc (AIM) Stock Analysis

Verdict: AVOID

Severe cash burn of $11M annually against $0.93M in reserves creates immediate insolvency and extreme dilution risk for AIM.

Investment score: 13/100

Analysis as of 2026-08-31

Is AIM ImmunoTech Inc stock worth reviewing? AI model thesis

The AI model rates AIM ImmunoTech as an AVOID due to severe cash depletion ($0.93M remaining), rapid annual operating cash burn (-$10.96M), and continuous earnings misses.

7-factor investment score

Valuation: 15/100 (weight 20%)
Financial Health: 5/100 (weight 15%)
Technical Momentum: 10/100 (weight 15%)
Earnings Quality: 5/100 (weight 15%)
Insider Sentiment: 20/100 (weight 10%)
Analyst Consensus: 30/100 (weight 10%)
Risk-Adjusted Return: 10/100 (weight 15%)

AIM ImmunoTech Inc opportunities and risks

What speaks for AIM

Phase 2 Clinical Data Milestones for Ampligen

What speaks against AIM

Imminent Insolvency and Cash Runway Exhaustion

Peers and competitors

Trailing-twelve-month ratios
Ticker	P/E	P/S	EV/EBITDA	Gross margin	Net margin	FCF yield
AIM	n/a	8.1x	0.4x	-125.3%	-15021.1%	-930.8%
ACXP	n/a	0.0x	0.6x	0.0%	0.0%	-27511.3%
SKYE	n/a	0.0x	0.0x	0.0%	0.0%	-525.9%
ADTX	n/a	522.1x	n/a	19.9%	-362385.7%	-248.2%
BOLT	n/a	1.6x	n/a	95.7%	-611.5%	-412.4%
AQB	n/a	0.0x	n/a	0.0%	0.0%	-60967.0%
Peer median	n/a	0.0x	n/a	0.0%	0.0%	-525.9%

Frequently asked questions about AIM ImmunoTech Inc (AIM)

Is AIM stock a good investment?

The cached TradeMates AI model rates AIM ImmunoTech Inc as AVOID with an investment score of 13/100. The AI model rates AIM ImmunoTech as an AVOID due to severe cash depletion ($0.93M remaining), rapid annual operating cash burn (-$10.96M), and continuous earnings misses. This is algorithmic model output, not personal investment advice.

Is AIM stock a buy?

The TradeMates model verdict for AIM is AVOID with an investment score of 13/100. Treat this as a model signal to review, not a personal buy recommendation.